Quick answerAs documented in research protocols, the Ipamorelin + Tesamorelin 10 mg blend vial is typically reconstituted with 3 mL of bacteriostatic water; the literature references about 330 mcg per dose. These figures reflect documented research protocols only and are provided for research-use-only reference, not medical guidance.
Fixed ratio: Ipamorelin 5 mg : Tesamorelin 5 mg — a 1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Reconstitution calculator
Mix & measure Ipamorelin + Tesamorelin · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Vial strengthmgBAC watermLYour dose
Concentration—mg/mL
Draw volume—mL
On the syringe—units
Doses / vial—
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Tesamorelin + Ipamorelin Dosage Chart & Reconstitution Guide
One combined 10 mg blend vial — total-blend dosing, once daily, step by step
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
▪
Reconstitute: Add 3.0 mL bacteriostatic water to the single 10 mg blend vial → ~3.33 mg/mL total peptide (3,333 mcg/mL).
▪
Total daily dose: Weeks 1–4 at 330 mcg total, then Weeks 5–8 at 500 mcg total, once daily (or 5 days on, 2 off).
▪
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33 mcg total blend on a U-100 syringe — 330 mcg = 10 units, 500 mcg = 15 units.
▪
50/50 split: Because both peptides share the vial, each total dose is roughly half Ipamorelin and half Tesamorelin (e.g. 330 mcg ≈ ~165 mcg Ipamorelin + ~165 mcg Tesamorelin).
Phase / Week(s) Total Blend Dose & Frequency Volume (U-100 units / mL) Weeks 1–4 330 mcg total (1× daily) 10 units (0.10 mL) Weeks 5–8 500 mcg total (1× daily) 15 units (0.15 mL)
Ask what generic AI won't
ChatGPT dodges your Ipamorelin + Tesamorelin dosing questions. OpenPeptide answers them.
Documented protocols, exact reconstitution math, and real sources — no lectures, no dead ends.
Why researchers study it
Why Ipamorelin + Tesamorelin draws research interest
These are the directions researchers and the peptide community most often explore Ipamorelin + Tesamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
GH & IGF-1 support
Studied for stimulating pulsatile growth hormone release, pairing a ghrelin agonist with a GHRH analog to raise IGF-1.
Visceral fat / lipolysis
Tesamorelin is FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy; this blend itself is not approved.
Body composition
Explored in research on lean mass and fat distribution through the GH/IGF-1 axis; investigational for this use, not approved.
Sleep & recovery
Investigated in preclinical work on slow-wave sleep and tissue repair tied to nocturnal growth hormone pulses.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
01 · At a glance
Quickstart Highlights
This page covers a single 10 mg combined blend vial that holds Ipamorelin 5 mg + Tesamorelin 5 mg together. Tesamorelin is a stabilized GHRH(1–44) analog and Ipamorelin is a selective ghrelin / GHS-R1a agonist; pairing them is intended to stimulate the growth-hormone axis from two angles[1][4]. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved, and this blend and its dosing are not clinically validated. Presented for research and educational use only.
Reconstitute
Add 3.0 mL bacteriostatic water to the single 10 mg blend vial → ~3.33 mg/mL total peptide (about 1.67 mg/mL of each).
Daily range
330–1000 mcg total blend once daily (or 5 days on, 2 off) across an 8–12 week cycle; each dose splits roughly 50/50 between the two peptides.
Easy measuring
At ~3.33 mg/mL, 1 unit ≈ 33 mcg total; 330 mcg ≈ 10 units and 500 mcg ≈ 15 units on a U-100 syringe.
Storage
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
i
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
02 · Dosing & reconstitution
Advanced / Aggressive Approach (2 mL = 5 mg/mL)
▪
Reconstitute: Add 2.0 mL bacteriostatic water to the single 10 mg blend vial → 5 mg/mL total peptide (5,000 mcg/mL).
▪
Total daily dose: Weeks 1–4 at 500 mcg total, then Weeks 5–8 at 1000 mcg total, once daily (or 5 days on, 2 off).
▪
Easy measuring: At 5 mg/mL, 1 unit ≈ 50 mcg total blend on a U-100 syringe — 500 mcg = 10 units, 1000 mcg = 20 units.
▪
50/50 split: Each total dose is about half of each peptide (e.g. 1000 mcg ≈ ~500 mcg Ipamorelin + ~500 mcg Tesamorelin).
Phase / Week(s) Total Blend Dose & Frequency Volume (U-100 units / mL) Weeks 1–4 500 mcg total (1× daily) 10 units (0.10 mL) Weeks 5–8 1000 mcg total (1× daily) 20 units (0.20 mL)
Frequency: one subcutaneous injection each day (or a 5-on / 2-off schedule), over an 8–12 week cycle. The numbers below come from commonly cited reference schedules, not from approved human dosing of this blend.
Reconstitution Steps
1
Draw 3.0 mL (Standard) or 2.0 mL (Advanced) of bacteriostatic water into a sterile syringe.
2
Release it slowly down the vial's inner wall to limit foaming.
3
Swirl or roll the vial gently until both peptides fully dissolve — don't shake.
4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Note
With daily dosing at 500 mcg or higher, a single 10 mg blend vial may last only about 10–20 days — plan vial counts accordingly. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
03 · What you'll need
Supplies Needed
Quantities below assume an 8–12 week course of once-daily injections from the combined 10 mg blend vial.
✓Peptide Vials (Ipamorelin + Tesamorelin, 10 mg Blend)
At higher daily doses one 10 mg blend vial may last only ~10–20 days, so plan multiple vials for a full cycle.
Lower dose (~330 mcg/day): 1 vial ≈ 4 weeks 8 weeks: ~2–4 vials 12 weeks: ~3–6 vials
✓Insulin Syringes (U-100, 1 mL)
Per injection: 1 syringe 8 weeks (once daily): ~56 syringes 12 weeks (once daily): ~84 syringes
✓Bacteriostatic Water (10 mL bottles)
Use 2–3 mL per 10 mg blend vial for reconstitution.
8 weeks: ~1–2 bottles 12 weeks: ~2 bottles
✓Alcohol Swabs
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen for the combined Ipamorelin + Tesamorelin blend, drawn from commonly cited reference protocols.
▪Goal: Investigate dual growth-hormone-axis stimulation and body-composition effects — theoretical synergy that is not validated for this blend. ▪Schedule: Once daily, or 5 days on / 2 days off, for an 8–12 week cycle. ▪Dose Range: 330–1000 mcg total blend per day, raised gradually; each dose splits ~50/50 between the two peptides. ▪Reconstitution: 3.0 mL (~3.33 mg/mL) for the Standard approach or 2.0 mL (5 mg/mL) for the Advanced approach, per 10 mg blend vial. ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze.
Dosing Protocol
A suggested daily titration approach for the combined blend, based on common reference doses.
▪Start: Begin at 330 mcg total once daily (Standard) to gauge tolerability. ▪Titrate: Step up to 500 mcg total around week 5; Advanced users run 500 → 1000 mcg. ▪Target: Reach 500–1000 mcg total daily by weeks 5–8, depending on approach. ▪Cycle Length: Typically 8–12 weeks, then assess or break before the next cycle. ▪Timing: Inject at a consistent time each day (evenings are common) and rotate injection sites.
Storage Instructions
Correct storage is what preserves both peptides' stability and activity.
▪Lyophilized: Hold the dry blend vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure. ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution. ▪Handling: Let a frozen vial warm to room temperature before opening so condensation won't form, and keep the solution clear of heat and direct light. ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
04 · Good to know
Important Notes
Practical points that keep daily administration safe and consistent.
▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward. ▪Volume tracking: The reconstitution volume sets the mcg per unit — track it carefully so your total-blend dose stays accurate. ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy. ▪Monitoring: Because this drives the GH axis, watch glucose and (where relevant) IGF-1 at higher doses, and log observations across the cycle. ▪Regulatory note: Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved. Both are WADA-prohibited (class S2), and this blend is not approved for human use.
05 · How it works
How This Works
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone GHRH(1–44). It binds pituitary GHRH receptors to drive a pulsatile release of growth hormone, which in turn raises IGF-1; clinically it reduces visceral (deep abdominal) fat[1][2].
Ipamorelin works through a different door: it is a selective ghrelin / GHS-R1a agonist that triggers a clean GH pulse with little effect on cortisol or prolactin[4]. Because the two act on separate receptors, combining them is intended to stimulate the GH axis from two angles at once.
Important caveat: the idea that a GHRH analog plus a ghrelin agonist produce additive or synergistic GH output is a reasonable hypothesis, but it has not been validated for this specific blend or its dosing. Read the body-composition and “synergy” framing as theory, not established clinical fact.
Approval status (mixed): Tesamorelin (Egrifta / Egrifta SV) is FDA-approved, but only for HIV-associated lipodystrophy — body-composition, muscle and anti-aging use is off-label. Ipamorelin is not FDA-approved (a research chemical, 503A category 2). The blend is presented for research and educational purposes only.
06 · Daily habits
Lifestyle Factors
Habits that may support outcomes alongside a GH-axis protocol.
▪Nutrition: Keep protein intake adequate and total calories aligned with your body-composition goal. ▪Activity & rest: Pair resistance training with real recovery time, since GH effects track with both stimulus and rest. ▪Sleep: Aim for 7–9 hours — the largest natural GH pulses occur during deep sleep. ▪Timing of carbs: Some protocols inject fasted or away from large carbohydrate meals, since elevated insulin can blunt the GH pulse.
07 · What to expect
Potential Benefits & Side Effects
What the framing of each peptide suggests; effects of the combined blend are not clinically established and individual results vary.
Potential Benefits
▪Visceral fat (Tesamorelin): In its approved HIV-lipodystrophy use, Tesamorelin reduces deep abdominal fat and raises IGF-1. ▪GH pulse (Ipamorelin): A clean, selective GH release is the rationale for stacking it with a GHRH analog. ▪Theoretical synergy: Dual-axis stimulation is proposed to support lean mass, recovery and body composition — not validated for this blend. ▪Note on humans: The combined blend has no completed efficacy trials; treat body-comp claims as hypotheses.
Common Side Effects
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps. ▪Fluid retention & GI: GH-axis stimulation can cause water retention, joint aches or mild nausea/GI discomfort. ▪Glucose / IGF-1: Higher GH output can affect insulin sensitivity; monitor glucose and IGF-1 at higher doses. ▪Sport restriction: Both peptides are WADA-prohibited (class S2) for athletes.
08 · Injection technique
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[5][6].
Pre-Injection Preparation
▪Wash your hands well with soap and water. ▪Wipe the vial stopper with an alcohol swab and let it air-dry. ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[6]. ▪Draw the intended total-blend dose, then check for air bubbles and push any out.
Injection Procedure
▪Pinch a skinfold at the chosen site between thumb and forefinger. ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[5]. ▪Skip aspiration for subcutaneous shots — it isn't needed[5]. ▪Press the plunger slowly and steadily until it's fully down. ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle. ▪Return the reconstituted vial to the fridge right away. ▪Rotate the injection site each day to prevent irritation and lipohypertrophy. ▪Watch the site for excess redness, swelling, or signs of infection.
09 · Where to source
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition. ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch. ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain. ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →
10 · The evidence
References
1
FDA Label — Egrifta (tesamorelin)
Prescribing information for tesamorelin, FDA-approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy.
View Source ↗ 2
New England Journal of Medicine (PubMed)
Randomized trials of tesamorelin showing reduced visceral adipose tissue and raised IGF-1 in HIV-associated lipodystrophy.
View Source ↗ 3
Clinical Infectious Diseases (PubMed)
Long-term tesamorelin data on visceral fat, IGF-1 and metabolic safety.
View Source ↗ 4
European Journal of Endocrinology (PubMed)
Ipamorelin characterized as a selective ghrelin / GHS-R1a agonist producing a GH pulse with minimal cortisol or prolactin effect.
View Source ↗ 5
CDC — Injection Safety / Best Practices
Guidance on safe injection technique, needle angle and disposal of sharps.
View Source ↗ 6
WHO Best Practices for Injections
Subcutaneous injection technique, site preparation and rotation guidance.
View Source ↗ 7
WADA Prohibited List (S2)
Growth hormone secretagogues including GHRH analogs and ghrelin / GHS-R1a agonists are prohibited at all times under class S2.
View Source ↗